Dutch company buys Stevenage facility from GSK
Netherlands-based Kadans Science Partner has laid the foundations for future growth in the UK Research & Development arena with the acquisition of Sycamore House in Stevenage from GSK.
Sycamore House is a 9,640 sq m industrial and warehouse building located directly adjacent to Stevenage Bioscience Catalyst and the Cell and Gene Therapy Catapult Manufacturing Centre.
Kadans will redevelop and extend the Sycamore House into a modern, vibrant, multi-tenanted R & D facility with expected completion mid-2021. The building will provide grow-on space for overflowing demand from the catalyst and catapult.
Discussions with potential occupiers are being progressed in collaboration with SBC to ensure that the offering is built to suit the needs of the campus community.
Situated in the heart of the Golden Triangle, centrally between Cambridge and London, the cluster benefits from good connectivity with established knowledge centres and a skilled workforce in close proximity.
The facility will build on the strengths of the collaborative ecosystem based at Stevenage and support the further growth of the globally significant cell and gene therapy community.
Kadans and SBC will develop the campus ecosystem through new initiatives and value-add services. The aim will be to support the cross-campus community both locally as well as internationally, using the networks and reach of both organisations.
Dr Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst, said: “We are delighted with this announcement and to work with Kadans as a long-term investor and developer in research intensive clusters.
“The campus is an established ecosystem of companies that have raised almost £1 billion of investment. The redevelopment of Sycamore House is an exciting new chapter in the expansion of this cluster in Stevenage.”
By adding Sycamore House to the portfolio, Kadans is furthering its aspiration to create one strong knowledge-sharing ecosystem of science parks across Europe. The portfolio now comprises 23 properties and four projects under development in the Netherlands, UK and Germany.
Mills & Reeve acted as legal adviser for Kadans.